An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations

Clinical Therapeutics

Volumn 27, Issue 12, 2005, Pages 1894-1900

  Saul Levinson, R ^a   Mitan, Steven J ^a   Steinmetz, Jana I ^a   Gattermeir, David J ^a   Schumacher, Robert J ^a   Joffrion, James L ^a  

^a KV Pharmaceutical Company   (United States)

Author keywords

Bioadhesive; Clindamycin; Pharmacokinetics; Systemic exposure; Vaginal cream; Vaginosis

Indexed keywords

CLINDAMYCIN; CLINDAMYCIN PHOSPHATE;

ABDOMINAL DISEASE; ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BREATHING RATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOTENSION; MATHEMATICAL COMPUTING; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VALIDATION PROCESS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINDAMYCIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 33644502546     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.12.006     Document Type: Article

References (13)

1. Koumans E.H., Kendrick J.S. CDC Bacterial Vaginosis Working Group Preventing adverse sequelae of bacterial vaginosis: A public health program and research agenda Sex Transm Dis. 28 2001 292 297
2. Sobel J.D. Vaginitis N Engl J Med. 337 1997 1896 1903
3. Gravett M.G., Nelson H.P., and DeRouen T. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome JAMA 256 1986 1899 1903
4. McGregor J.A., French J.I., and Jones W. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: Results of a controlled trial of topical clindamycincream Am J Obstet Gynecol. 170 1994 1048 1059
5. Hillier S.L., Nugent R.P., Eschenbach D.A. Vaginal Infections and Prematurity Study Group Association between bacterial vaginosis and preterm delivery of a low-birthweight infant N Engl J Med. 333 1995 1737 1742
6. Sweet R.L. Role of bacterial vaginosis in pelvic inflammatory disease Clin Infect Dis. 20 Suppl 2 1995 5271 5275
7. Soper D.E. Bacterial vaginosis and postoperative infections Am J Obstet Gynecol. 169 1993 467 469
8. Richter A., Anton S.E., Koch P., and Dennett S.L. The impact of reducing dose frequency on health outcomes Clin Ther. 25 2003 2307 2335
9. Thompson D.J., and Levinson R.S. A bioadhesive topical drug delivery system Drug Deliv Sys Sci. 2 2002 17 19
10. Merabet J., Thompson D., and Levinson R.S. Advancing vaginal drug delivery Expert Opin Drug Deliv. 2 2005 769 777
11. Weinstein L., Henzel M.R., and Tsina I.W. Vaginal retention of 2% butoconazole nitrate cream: Comparison of a standard and a sustained-release preparation Clin Ther. 16 1994 930 934
12. Faro S., Skokos C.K. Clindesse Investigators Group The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterialvaginosis Infect Dis Obstet Gynecol. 13 2005 155 160
13. Available at World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Accessed November 14 2005